124 results on '"Huh, Warner"'
Search Results
2. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
3. Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report
4. Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors
5. Adjuvant Chemotherapy Following Chemo-Radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-Radiation Alone: The Randomised Phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)
6. Identity-related experiences of Asian American trainees in gynecologic oncology
7. Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study
8. Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients
9. Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management
10. Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)
11. Increased disparities associated with black women and abnormal cervical cancer screening follow-up
12. Safety and feasibility of an HPV therapeutic vaccine (TA-CIN) in patients with HPV16 associated cervical cancer (458)
13. Piloting use of an out-of-pocket cost tracker among gynecologic cancer patients
14. Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women
15. Effect of Misoprostol on Type 3 Transformation Zone of the Cervix among Cameroonian Women
16. Misoprostol and estradiol to enhance visualization of the transformation zone during cervical cancer screening: An integrative review
17. Corrigendum to “Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis” [Gynecologic Oncology 162 (2021) 532–538]
18. Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study
19. Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis
20. Attitudes and knowledge of HPV vaccination in women being treated for an abnormal Pap smear
21. Pathology findings among women with alterations in uterine bleeding patterns in cameroon
22. Impact of implementation of a nutrition support program in ovarian cancer patients
23. It's time to re-evaluate cervical Cancer screening after age 65
24. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients
25. The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
26. Fluorescence Imaging of the Ureter in Minimally Invasive Pelvic Surgery
27. Estimating the time and travel costs for gynecologic cancer care – more than just money
28. 51st Annual Meeting of the Society of Gynecologic Oncology
29. Risk of second primary cancers among survivors of gynecological cancers
30. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
31. When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic
32. Human papillomavirus: The other invisible enemy
33. Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II
34. Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I
35. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
36. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
37. Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers
38. Human papillomavirus vaccination: Ongoing challenges and future directions
39. Extensive financial hardship among gynecologic cancer patients starting a new line of therapy
40. Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report
41. Corrigendum to “Financial toxicity – An overlooked side effect” [Gynecol. Oncol. 150 (2018) 3–6]
42. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
43. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
44. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
45. Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution
46. The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction
47. Catch-up human papillomavirus vaccination: don't throw the baby out with the bathwater
48. A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer
49. Financial toxicity – An overlooked side effect
50. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.